Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data-Reference-Cited by-同舟云学术

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

Published:2015-12-18 Issue:2 Volume:63 Page:437-444
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Wilder Julius M.¹,Jeffers Lennox J.²,Ravendhran Natarajan³,Shiffman Mitchell L.⁴,Poulos John⁵,Sulkowski Mark S.⁶,Gitlin Norman⁷,Workowski Kimberly⁸,Zhu Yanni⁹,Yang Jenny C.⁹,Pang Phillip S.⁹,McHutchison John G.⁹,Muir Andrew J.¹,Howell Charles¹⁰,Kowdley Kris¹¹,Afdhal Nezam¹²,Reddy K. Rajender¹³

Affiliation:

1. Duke Clinical Research InstituteDurham NC

2. Miami VA Medical CenterMiami FL

3. Digestive Disease AssociatesBaltimore MD

4. Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News VA

5. Fayetteville Gastroenterology Associates, Cumberland Research AssociatesFayetteville NC

6. Johns Hopkins University School of MedicineBaltimore MD

7. Atlanta Gastroenterology AssociatesAtlanta GA

8. Emory UniversityAtlanta GA

9. Gilead Sciences, Inc.Foster City CA

10. Howard UniversityWashington DC

11. Swedish Medical CenterSeattle WA

12. Beth Israel Deaconess Medical CenterBoston MA

13. University of Pennsylvania School of MedicinePhiladelphia PA

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28334

Reference15 articles.

1. Global epidemiology of hepatitis C virus infection

2. The global burden of hepatitis C

3. Centers for Disease Control and Prevention.Hepatitis C information for health professionals Atlanta 2008.http://www.cdc.gov/hepatitis/hcv/. Accessed on July 10 2015.

4. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

5. National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state‐of‐the‐science statements. Bethesda MD: National Institutes of Health; July 2002.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C in Black Individuals in the US;JAMA;2023-12-12

2. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections;Archives of Virology;2022-01-28

3. Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center;Journal of Racial and Ethnic Health Disparities;2021-07-12

4. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?;International Journal of Infectious Diseases;2021-06

5. Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations;Clinical Trials;2020-07-10